Chemours (NYSE: CC) Securities Class Action: Opteon Demand, Channel Inventory and December 7, 2026 Lead Plaintiff Deadline

The securities complaint focuses on Chemours's Opteon refrigerants, which benefited from the U.S. transition toward lower-global-warming-potential refrigerants under the AIM Act. Plaintiff alleges that Chemours overstated sustainable aftermarket demand after unusually strong sales associated with an initial inventory build during 2025.

According to the complaint, some of that demand had been pulled forward into 2025 — leaving customers with excess inventory entering 2026 — while management continued to express confidence in aftermarket demand and in its full-year 2026 guidance. This is best understood as an Opteon-demand, channel-inventory, and financial-guidance disclosure case, not simply a claim that 'Chemours lowered guidance.' The allegations have not been proven.

The Chemours Company is a global specialty-chemicals company headquartered in Wilmington, Delaware, reporting through three principal segments: Thermal & Specialized Solutions (TSS), Titanium Technologies (TT), and Advanced Performance Materials (APM). This case focuses principally on the TSS segment and, within it, Chemours's Opteon refrigerants.

Chemours is incorporated in Delaware, and its common shares trade on the New York Stock Exchange under CC. The complaint names President and CEO Denise Dignam and Senior Vice President and CFO Shane Hostetter as the individual defendants.

Opteon is Chemours's portfolio of lower-global-warming-potential refrigerants — with a near-zero ozone-depletion footprint — used in applications such as residential air conditioning, commercial refrigeration, automotive air conditioning, chillers, and other thermal-management uses. Chemours reports Opteon sales primarily through its TSS segment.

The American Innovation and Manufacturing Act of 2020 (the AIM Act) directs the EPA to phase down hydrofluorocarbons and move certain industries toward lower-global-warming-potential refrigerants. Beginning January 1, 2025, EPA restrictions began applying to many new residential and light-commercial air-conditioning products using higher-GWP refrigerants, which required HVAC manufacturers, distributors, and technicians to prepare for new refrigerants — and helped drive strong demand for products in Chemours's Opteon portfolio.

The lawsuit concerns whether some of that unusually strong initial demand represented continuing underlying aftermarket consumption, or instead an unusually large one-time inventory build pulled forward from later periods.

A 'channel fill' occurs when distributors, wholesalers, technicians, or other intermediaries stock up on inventory ahead of expected customer demand. Those purchases count as sales for the manufacturer right away. But if the channel initially buys more than customers ultimately consume, later orders can slow while distributors work down the existing inventory — a process often called 'destocking.'

This is not automatically improper — companies routinely experience inventory builds, prebuys, destocking, and seasonal swings. The securities question is narrower: whether Chemours allegedly knew that 2025 demand had materially pulled sales forward while continuing to tell investors that aftermarket demand remained strong enough to support its 2026 expectations.

The class period begins February 20, 2026, the morning after Chemours released its Q4 and full-year 2025 results. Chemours reported a record fourth quarter for TSS, with Opteon refrigerant sales up approximately 37% year over year, and it guided 2026 to adjusted EBITDA of $800 million–$900 million and net-sales growth of about 3%–5%.

Management attributed the performance to higher pricing, moderate volume increases, a favorable Opteon product mix, the AIM Act-driven residential HVAC transition, and commercial execution. On the earnings call, CEO Denise Dignam told investors, 'We have full confidence in our full year guide.' The complaint highlights that statement because the full-year guidance was later lowered.

Yes — and this is an important distinction. Management expressly told investors in February that Opteon's year-over-year growth would begin to normalize later in 2026 as comparisons caught up with the unusually strong regulatory-transition demand from late 2025; it projected possible double-digit Opteon growth through Q2 before second-half comparisons became harder.

So plaintiff does not merely allege that Chemours failed to warn that growth would slow. The complaint's theory is narrower: that management still understated the magnitude of the customer-inventory overhang created by the 2025 channel fill, and therefore overstated the aftermarket demand embedded in its 2026 guidance.

On May 5, 2026, Chemours reported approximately $1.4 billion in net sales, record first-quarter TSS performance, continued double-digit year-over-year Opteon growth, and adjusted EBITDA of $169 million. The company reaffirmed its $800 million–$900 million full-year adjusted-EBITDA guidance.

Yes. On the May earnings call, CFO Shane Hostetter disclosed approximately $10 million of adjusted-EBITDA impact associated with demand and sales that had been pulled forward into Q1, and said it would modestly temper Q2 sequential improvement.

So it would be inaccurate to say Chemours disclosed no pull-forward before August. The complaint's stronger argument is that Chemours disclosed a relatively limited Q1 timing pull-forward while allegedly failing to disclose the much larger inventory effect created by the 2025 initial channel fill.

On the May call, in response to an analyst asking about TSS after the AIM Act transition, Dignam said Chemours still expected year-over-year Opteon/TSS growth and that the company had 'a really, really strong position in the aftermarket.' Management also maintained its 2026 guide and said it remained 'bullish' on TSS opportunities. Plaintiff alleges the aftermarket statement was misleading because excess channel inventory was allegedly already weighing on aftermarket demand.

After the market closed on August 4, 2026, Chemours released Q2 results and reduced its full-year adjusted-EBITDA guidance from $800 million–$900 million to $775 million–$825 million. It reported approximately $1.6 billion of Q2 net sales, down about 1% year over year, attributing the decline partly to lower TSS Opteon-blend aftermarket refrigerant demand.

On the August 5 call, management explained that the 2025 AIM Act transition had created advanced demand tied to the initial aftermarket channel fill, and that customers had then built additional inventory. Dignam said that had created 'an oversupplied channel heading into 2026' — the single most important factual phrase in the case.

CFO Shane Hostetter told analysts that approximately $65 million of aftermarket sales affecting the Q2 and Q3 year-over-year comparison had effectively been realized earlier, during the 2025 regulatory transition — a 'prebuy' related to inventory constraints and available supply. Plaintiff alleges investors should have been told sooner that the prior-year channel fill had materially reduced later aftermarket demand.

Importantly, the $65 million figure is not an accounting restatement of previously reported revenue. It is a commercial-demand timing comparison — about when demand occurred, not a correction of recognized GAAP revenue.

No. TSS remained highly profitable. For Q2 2026, Chemours reported approximately $591 million of TSS sales, $213 million of TSS adjusted EBITDA, and a 36% TSS adjusted-EBITDA margin — with TSS adjusted EBITDA up roughly 3% year over year — alongside company operating cash flow of $158 million and free cash flow of $114 million. (Opteon refrigerant sales were about $337 million, versus roughly $375 million in Q2 2025, an approximately 10% decline.)

The securities complaint concerns the sustainability and disclosure of aftermarket demand — not an allegation that TSS had become unprofitable.

No. Chemours lowered and narrowed its 2026 adjusted-EBITDA range to $775 million–$825 million and revised expected net-sales growth from about 3%–5% to about 1%–5%. It continued to forecast positive free cash flow, pricing momentum, APM demand, cost improvements, and deleveraging. The guidance was reduced, not withdrawn.

According to the complaint, CC fell from an August 4 closing price of approximately $17.93 to $14.59 on August 5 — a decline of $3.34, or approximately 18.63%. The complaint also cites several analysts lowering their price targets after the disclosure (for example, UBS to $18 from $29, Morgan Stanley to $18 from $21, and J.P. Morgan to $15 from $22). Those are analyst opinions, not independent proof of the allegations.

No. A separate Chemours securities case — The Chemours Company Securities Litigation, No. 24-361-RGA (D. Del.) — arises from the company's 2024 Audit Committee internal review and involves a February 10, 2023–February 28, 2024 class period and allegations about working-capital practices, executive-compensation metrics, internal controls, non-GAAP reporting, and actions by former executives.

The current Darcy case instead concerns 2026 statements by current CEO Denise Dignam and CFO Shane Hostetter about Opteon, the AIM Act transition, aftermarket demand, channel inventory, and 2026 guidance. As for the earlier case, in May 2026 the court dismissed the amended complaint without prejudice (principally for not adequately pleading a material misrepresentation); plaintiffs filed another amended complaint, and Chemours reported that further dismissal briefing was underway.

The complaint alleges that CEO Denise Dignam and CFO Shane Hostetter disposed of approximately 26,671 shares during the class period. The underlying SEC Forms 4, however, identify the transactions cited in the complaint as automatic share withholding to satisfy tax obligations — not discretionary open-market sales. For the reviewed Dignam transactions, the filings expressly state, 'No shares were sold.'

Julie & Holleman therefore does not characterize these transactions as evidence of insider selling based on the currently available filings. In fact, after the August decline both executives made open-market purchases — Hostetter bought approximately 3,350 shares on August 6, and Dignam approximately 3,378 shares on August 11. Those purchases do not determine whether the securities allegations are valid, but they are relevant context when evaluating any insider-transaction theory.

Section 10(b) and Rule 10b-5

The complaint asserts federal securities-fraud claims under Section 10(b) and Rule 10b-5 against Chemours and the individual defendants.

Section 20(a)

The complaint asserts controlling-person claims against Denise Dignam and Shane Hostetter.

The alleged class period is February 20, 2026 through August 4, 2026, inclusive.

Investors should preserve all brokerage statements and transaction records showing CC purchases and sales during the class period.

The current published PSLRA lead plaintiff deadline is December 7, 2026, as identified in the PSLRA notice published by Pomerantz.

Do I Have to Become Lead Plaintiff?

Generally, no. A lead plaintiff is the investor or investor group the court selects to actively oversee the proposed class and proposed lead counsel. Most investors remain passive class members.

Lead Plaintiff Deadline ≠ Settlement Claim Deadline

These are different dates. A passive class member generally need not seek lead-plaintiff appointment merely to remain potentially eligible for a later class recovery.

Generally, no, for a securities-class claim. Selling the shares does not automatically eliminate a securities claim, though purchase and sale dates can affect damages and recognized loss. Continued ownership presents separate requirements for derivative claims.

Potentially — but with an important caveat: Chemours already has derivative litigation. The company received at least seven Delaware Section 220 books-and-records demands during 2024 concerning alleged management wrongdoing, executive compensation, and oversight of accounting practices; two derivative actions were filed in Delaware state court in April 2025 and a third in June 2025 (since consolidated and stayed), and Chemours also received a shareholder litigation demand in June 2025. So this is not a first-of-its-kind derivative matter.

Chemours is a Delaware corporation. Julie & Holleman LLP is investigating whether the newer Opteon-demand and channel-inventory allegations may give current Chemours shareholders additional, distinct, or overlapping shareholder derivative and corporate-governance rights beyond the accounting-related derivative litigation already pending. Because different alleged acts occurred in February, May, and August, a shareholder who acquired CC after February 20 could potentially have contemporaneous ownership for later challenged acts; we are interested in speaking with current shareholders who owned CC at the time of potentially actionable conduct and have continued to hold their shares. Potential areas of investigation include:

• channel-inventory oversight — distributor and aftermarket stock levels, sell-in versus sell-through, and the timing of the 2025 channel fill;
• the guidance process — what assumptions supported the $800–$900 million EBITDA guide, how much aftermarket demand was assumed, and when forecasts were revised internally;
• sales pull-forward — how much 2025 demand represented initial inventory stocking, and whether the roughly $65 million effect was identified internally before August;
• disclosure controls — how statements such as 'full confidence' and 'a really, really strong position in the aftermarket' were reviewed; and
• board oversight — what the Board was told about Opteon channel inventories, customer destocking, and forecast changes.

Counsel may evaluate whether additional Delaware books-and-records or other investigative steps concerning the newer Opteon and channel-inventory allegations are appropriate, in light of the existing shareholder litigation and prior demands. No determination has been made that additional claims exist or are non-duplicative of the existing derivative litigation.

No. The Darcy securities lawsuit concerns allegedly misleading investor statements about Opteon refrigerant aftermarket demand and Chemours's 2026 financial guidance. It is separate from Chemours's PFAS environmental litigation and settlements.

Julie & Holleman LLP is investigating allegations involving Chemours, CC, Opteon, the TSS segment, the AIM Act transition, aftermarket demand, channel inventory, 2026 financial guidance, disclosure controls, and board oversight. We are interested in hearing from:

Investors With Securities Losses

Investors who purchased or otherwise acquired Chemours securities between February 20, 2026 and August 4, 2026 and suffered losses, including investors evaluating lead-plaintiff appointment before December 7, 2026.

Current CC Shareholders

Current shareholders who owned CC during potentially actionable Opteon-related conduct and continue to hold shares and wish to evaluate potential additional derivative or corporate-governance rights.

A shareholder may potentially fall within both groups.